“Amit Khurana views Sun Pharma's recent acquisition as strategically sound and directionally correct for long-term growth, particularly in biosimilars, considering the equity valuation reasonable. While the nearly $10 billion debt component is a significant concern that requires careful navigation, he believes it is largely manageable if execution and product scalability remain on track over the next few years.”